A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A

UMIN ID: UMIN000001535

Registered date:01/01/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Charcot-Marie-Tooth disease 1A
• Date of first enrollment: 2005/04/01
• Target sample size: 60
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day)
no AA treatment group

Outcome(s)

• Primary Outcome: An improvement in CMT neuropathy score at baseline, 4, 8 and 12 weeks thereafter.
• Secondary Outcome: An improvement in muscle strength and ulnar nerve conduction study at baseline, 4, 8 and 12 weeks thereafter.

Key inclusion & exclusion criteria

• Age minimum: 15years-old
• Age maximum: 75years-old
• Gender: Male and Female
• Exclude criteria: 1) Patients with dementia 2) Patients with severe complications 3) Patients who are not appropriate for the trial by the decision of the physician in charge

Related Information

• Primary Sponsor: New treatment strategies for intractable neuropathies based on its pathomechanism. The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.
• Source(s) of Monetary Support: New treatment strategies for intractable neuropathies based on its pathomechanism. The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.